Basetty N Rajarathnam, Nagaraju Rakesh, Anita Murali, J Anbu, & M L Asha. (2023). Cysteamine hydrochloride, a transglutaminase2 inhibitor as therapeutic potential for oral submucous fibrosis. Wolters Kluwer Medknow Publications.
Chicago Style (17th ed.) CitationBasetty N Rajarathnam, Nagaraju Rakesh, Anita Murali, J Anbu, and M L Asha. Cysteamine Hydrochloride, a Transglutaminase2 Inhibitor as Therapeutic Potential for Oral Submucous Fibrosis. Wolters Kluwer Medknow Publications, 2023.
MLA (9th ed.) CitationBasetty N Rajarathnam, et al. Cysteamine Hydrochloride, a Transglutaminase2 Inhibitor as Therapeutic Potential for Oral Submucous Fibrosis. Wolters Kluwer Medknow Publications, 2023.
Warning: These citations may not always be 100% accurate.